Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions

To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.

Participants needed: 36
Trial details
Phase: Phase 1Age: 19-54Biological sex: MaleType: InterventionalSponsor: AJU Pharm Co., Ltd.Updated: Jun 11, 2026Locations: 1
Eligibility criteria

Healthy male adults aged ≥19 years and <55 years at screening. [+4]

Use of medications known to induce or inhibit drug-metabolizing enzymes within 3... [+5]

Read more
Status: Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults after taking the drugs with food (fed state).

Participants needed: 32
Trial details
Phase: Phase 1Age: 19-50Biological sex: AllType: InterventionalSponsor: AJU Pharm Co., Ltd.Updated: Jul 1, 2025Locations: 1
Eligibility criteria

Healthy adult volunteers aged 19 to 50 years at the time of screening. [+7]

Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days... [+15]

Read more
Status: Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

Participants needed: 50
Trial details
Phase: Phase 1Age: 19-50Biological sex: AllType: InterventionalSponsor: AJU Pharm Co., Ltd.Updated: Jun 24, 2025Locations: 1
Eligibility criteria

Healthy adult volunteers aged 19 to 50 years at the time of screening. [+7]

Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days... [+15]

Read more